Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]

ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with...

Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center...

ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL ( Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene, USA )

PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell...

Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA

PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma ( Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA )

Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory...

Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center

$Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia ( Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center )$

GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy?

Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA

GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy? ( Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA )

Predicting early relapse in transplant-eligible MM patients using baseline...

Dr Francesca Gay - University of Torino, Torino, Italy

Predicting early relapse in transplant-eligible MM patients using baseline prognostic features and MRD negativity ( Dr Francesca Gay - University of Torino, Torino, Italy )

Using multiparameter flow cytometry and next generation sequencing to evaluate...

Dr Francesca Gay - University of Torino, Torino, Italy

Using multiparameter flow cytometry and next generation sequencing to evaluate MRD in NDMM patients from the FORTE trial ( Dr Francesca Gay - University of Torino, Torino, Italy )

Complete remission after induction chemotherapy determines clinical efficacy of...

Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden

Complete remission after induction chemotherapy determines clinical efficacy of relapse-preventive immunotherapy in AML ( Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden )

FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible...

Prof David Cairns - University of Leeds, Leeds, UK

FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patients with NDMM ( Prof David Cairns - University of Leeds, Leeds, UK )

Myeloma highlights from ASH 2019

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Myeloma highlights from ASH 2019 ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

FLT3-inhibition in infants with acute lymphoblastic leukaemia

Dr Patrick Brown - Johns Hopkins University, Baltimore, USA

FLT3-inhibition in infants with acute lymphoblastic leukaemia ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )

Chronic lymphocytic leukaemia highlights from ASH 2019

Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia

Chronic lymphocytic leukaemia highlights from ASH 2019 ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer